India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol children aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect kids from the coronavirus.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organisation said.
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of US drugmaker Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
Sydney Airport flights disrupted due to air traffic controller shortage
Philippine firefighters enter charred ferry as search continues for dozens missing
More US lawmakers seek AI rules after Anthropic researchers warn of extinction
Fire in rebel-held east Congo kills 24 schoolchildren
Trump says he does not regret Iran war despite potential impact on elections
Trump touts $5,000 payout if Republicans win as Vance waits in wings
Search expands after Philippine ferry fire kills five and leaves dozens missing
Trump says Iran war to end after US midterm elections
